Edison Investment Research - Medlab Clinical (MDC) Medlab Clinical - Progressing on multiple fronts

Report

Edison Investment Research

Sean Conroy

Medlab Clinical - Progressing on multiple fronts

Medlab Clinical has announced that it has cleared the Securities Exchange Commission’s (SEC’s) comments on its Nasdaq listing and is now preparing to finalise its application with its US broker, Alliance Global Partners. After this announcement, we expect Medlab will remain on track to meet its listing target timeline of Q1 CY23, which coincides with the anticipated investigational new drug (IND) submission for NanaBis in the US (to start Phase III trials). Due to the high activity and liquidity associated with the US biotech market, the potential Nasdaq listing could support the company in progressing its development pipeline. Our valuation for Medlab remains unchanged at A$236.1m or A$103.5/share.

12/12/2022 1 EN

Underlying

Medlab Clinical

Medlab Clinical is engaged in the sale of nutraceutical products for chronic illnesses; pharmaceutical research; and development of platform technologies to repurpose existing drugs.

See profile

AU000000MDC8 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Medlab Clinical - NanaBis development centre stage in 2023

As Medlab Clinical moves into 2023, the expected commencement of a Phase III trial for NanaBis (the company’s cannabinoid based analgesic therapy) in cancer-induced bone pain will be the focus for investors. Management made considerable progress towards Phase III in 2022, by switching to a purely synthetic cannabinoid formulation and gathering encouraging real-world data on NanaBis use. We believe these actions should maximise the potential for NanaBis in both a regulatory and a commercial setting. We note that successful progression of the company’s programmes will be contingent on Medlab’s a...

January 23, 2023 January 23, 2023 1 EN

Edison Investment Research

Medlab Clinical - Encouraging real-world data to support NanaBis

Medlab Clinical has announced positive interim data from its real-world evidence study for NanaBis (Medcare observational study). The 12-month study comprised 1,172 patients (with both cancer and non-cancer related pain) and exhibited a good safety, tolerability and sustainability profile for NanaBis use. The enrolled patients reported a 55% improvement in pain relief, along with reduced opioid use in 75% of the patients. Importantly, 92% of the patients with cancer bone metastasis reported reduced pain severity and pain interference scores after six months. Final data are expected in July 202...

January 17, 2023 January 17, 2023 1 EN

GlobeNewsWire

MEDLAB ANNOUNCES FAVOURABLE INTERIM READOUT OF NANABIS™ REAL-WORLD EVIDENCE (RWE) MEDCARE STUDY

MEDLAB ANNOUNCES FAVOURABLE INTERIM READOUT OF NANABIS™ REAL-WORLD EVIDENCE (RWE) MEDCARE STUDY N=1,172 Australian pain patientsDatapoints collected from commencing NanaBis™ (baseline) up to month 1255% improvement in pain relief75% of patients reduced their opioid use31% Improvements in Quality of Life as it relates to pain interference92% of patients with bone metastasis from cancer had reduced their pain severity and pain interference (Quality of Life) scores at 6-monthsNew “ENHANCE” study expects to onboard March 2023 Sydney, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd ...

January 12, 2023 January 12, 2023 1 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Medlab Clinical - Progressing on multiple fronts

Medlab Clinical - NanaBis development centre stage in 2023

Medlab Clinical - Encouraging real-world data to support NanaBis

MEDLAB ANNOUNCES FAVOURABLE INTERIM READOUT OF NANABIS™ REAL-WORLD EVIDENCE (RWE) MEDCARE STUDY

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe